OakChart

Korro Bio Inc

KRROHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

14.41-1.32 (-8.39%)
2026-11-12 00:20 CET
Market cap
215.90 USD m
Revenue, TTM
1.29 USD m
Net income, TTM
-106.13 USD m
Free cash flow, TTM
-63.87 USD m
EPS diluted, TTM
-9.07
P/E
-
Compare

Price

KRRO against its 20, 50 and 200-day averages
2050200beatmiss
10.0012.5015.0017.50394K787KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26KRROclose 14.4120-day 13.0050-day 11.77200-day 12.1514.41

57.5% under the 52-week high of 33.92 on 12 Nov 2025. 52-week low 5.20 on 2 Dec 2025. Last 15 sessions, 91.0% high to low

Volume 1.08× normal · the line is the 50-bar volume average

Profile

KRRO
52-week range, 32% of the way up
5.2033.92

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

IndexRUT
Employees58
IPOOct 03, 2019
Beta3.19
ATR, 14d1.41
Rel volume1.08
Short float18.28%
Insider own30.28%
Inst own73.90%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap197.78M
Enterprise Value134.31M
Income-106.13M
Sales1.29M
Book/sh6.44
Cash/sh7.65
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees58
IPOOct 03, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S153.32
P/B2.24
P/C1.88
P/FCF-
EV/EBITDA-
EV/Sales104.12
Quick Ratio7.30
Current Ratio7.30
Debt/Eq0.47
LT Debt/Eq0.44
Option/ShortYes / Yes

Earnings

EPS (ttm)-9.07
EPS next Y-4.80
EPS next Q-1.25
EPS this Y60.84%
EPS next Y1.76%
EPS next 5Y31.38%
EPS past 3/5Y62.00% 21.21%
Sales past 3/5Y- -29.61%
EPS Y/Y TTM3.73%
Sales Y/Y TTM-82.47%
EPS Q/Q48.93%
Sales Q/Q-100.00%
EarningsNov 05 BMO
EPS/Sales Surpr.22.34% -100.00%

Ownership

Insider Own30.28%
Insider Trans-7.20%
Inst Own73.90%
Inst Trans11.73%
ROA-68.54%
ROE-113.26%
ROIC-83.68%
Gross Margin-41.56%
Oper. Margin-5796.05%
Profit Margin-8214.47%
SMA2010.82%
SMA5022.44%
SMA20018.57%
Trades-

Technical

Shs Outstand13.73M
Shs Float9.57M
Short Float18.28%
Short Ratio9.84
Short Interest1.75M
52W High33.92 -57.51%
52W Low5.20 176.88%
Volatility14.30% 11.76%
ATR (14)1.41
RSI (14)57.70
Beta3.19
Rel Volume1.08
Avg Volume177.77K
Volume192,705

Performance

Perf Week-13.30%
Perf Month63.56%
Perf Quarter8.43%
Perf Half Y28.66%
Perf YTD79.90%
Perf Year-56.07%
Perf 3Y-66.12%
Perf 5Y-95.52%
Perf 10Y-
Recom1.25
Target Price21.18
Prev Close15.73
Price14.41
Change %-8.39%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
May 18, 2026InitiatedCCitigroupBuy$21+45.7%
Mar 13, 2026UpgradeRRaymond JamesMkt Perform → Outperform$23+59.6%
Feb 17, 2026UpgradeWWilliam BlairMkt Perform → Outperform
Jan 29, 2026UpgradePPiper SandlerNeutral → Overweight$30+108.2%
Jan 29, 2026UpgradeHH.C. WainwrightNeutral → Buy$20+38.8%
Jan 29, 2026UpgradeCChardan Capital MarketsNeutral → Buy$15+4.1%
Jan 28, 2026UpgradeOOppenheimerPerform → Outperform$22+52.7%
Jan 28, 2026UpgradeCCantor FitzgeraldNeutral → Overweight$21+45.7%
Nov 13, 2025DowngradeWWilliam BlairOutperform → Mkt Perform
Nov 13, 2025DowngradeRRBC Capital MktsOutperform → Sector Perform$8-44.5%

Peers

Mkt cap
TickerCompanyMkt cap
PRQRProQR Therapeutics N.V177.81M
WVEWave Life Sciences Inc674.52M
ADRXADARx Pharmaceuticals Inc1.47B
SLNSilence Therapeutics Plc ADR1.23B
ARWRArrowhead Pharmaceuticals Inc6.97B
PRMEPrime Medicine Inc779.92M
BEAMBeam Therapeutics Inc2.67B
STOKStoke Therapeutics Inc1.82B
IONSIonis Pharmaceuticals Inc4.72B
ALNYAlnylam Pharmaceuticals Inc21.41B

Insider trading

latest 14 of 64
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Lynx1 Capital Management LP10% OwnerOct 22 '26Buy10.7252,175559,2741,597,155Oct 26 06:37 PM
Lynx1 Capital Management LP10% OwnerOct 26 '26Buy11.7525,124295,0911,624,789Oct 26 06:37 PM
Lynx1 Capital Management LP10% OwnerOct 23 '26Buy12.112,51030,3861,599,665Oct 26 06:37 PM
FORMELA JEAN FRANCOISDirectorSep 14 '26Sale14.1238,490543,479132,650Sep 15 04:15 PM
FORMELA JEAN FRANCOISDirectorSep 11 '26Sale13.9910,200142,698139,252Sep 15 04:15 PM
Atlas Venture Fund XI, L.P.ShareholderSep 14 '26Proposed Sale13.8131,888440,373Sep 14 04:58 PM
Atlas Venture Opportunity FundShareholderSep 14 '26Proposed Sale13.816,60291,174Sep 14 04:58 PM
Dolan OliverSenior Vice President, FinanceSep 11 '26Sale13.7256916,241Sep 14 04:05 PM
Atlas Venture Fund XI, L.P.ShareholderSep 11 '26Proposed Sale13.068,450110,357Sep 11 05:10 PM
Atlas Venture Opportunity FundShareholderSep 11 '26Proposed Sale13.061,75022,855Sep 11 05:09 PM
Dolan OliverOfficerSep 11 '26Proposed Sale13.72569Sep 11 04:25 PM
Dolan OliverSenior Vice President, FinanceSep 08 '26Sale13.517,34799,28616,252Sep 10 04:05 PM
Dolan OliverSenior Vice President, FinanceSep 09 '26Sale13.6068216,246Sep 10 04:05 PM
Dolan OliverOfficerSep 09 '26Proposed Sale13.60682Sep 09 04:21 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VXFVanguard Extended Market Index ETFAUM: 30.47B
LFSCF/m Emerald Life Sciences Innovation ETFAUM: 130.02M
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
VHTVanguard Health Care ETFAUM: 21.51B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 200
  • Korro to Present at the 2026 Jefferies Global Healthcare Conference in London (GlobeNewswire)
  • Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -11.37%
  • Kosmos Energy Shares Fall Over 10% After Q3 Earnings and Revenue Miss Forecasts (InvestorsHub) +10.69%
  • Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency (GlobeNewswire) +29.71%
  • Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.81%
  • Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121 (GlobeNewswire)
  • Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.74%
  • Korro to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +5.39%
  • Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.28%
  • Korro to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire) +11.60%
  • Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -8.22%
  • Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.12%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.980-1.262-0.9800.000.1912
2026Q22026-08-06-1.070-1.338-1.0740.000.2111
2026Q12026-05-07-1.690-1.727-1.6920.000.769
2025Q42026-03-12-5.330-2.070-5.3211.300.709
2025Q32025-11-12-1.920-2.594-1.9231.090.6510
2025Q22025-08-12-2.740-2.566-2.7441.460.4910
2025Q12025-05-07-2.490-2.582-2.4922.550.4310
2024Q42025-03-18-2.240-2.500-2.2612.250.008
2024Q32024-11-12-2.260-2.527-2.2570.000.006
2024Q22024-08-13-2.430-2.429-2.4290.000.003
2024Q12024-05-14-2.440-2.383-2.4390.000.004
2023Q42024-03-26-5.013-3.530-4.8920.000.004
2023Q32023-11-20-5.155-1.450-15.7280.000.001
2023Q22023-08-10-15.000-17.796-15.0780.000.004
2023Q12023-05-12-27.500-21.000-27.6630.000.004
2022Q42023-03-10-24.500-31.550-24.6190.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-114.5-36.833-32.09728.9532.53
2020FY-41.000-39.025-41.09836.9835.39
2021FY-123.5-84.263-123.2714.0745.07
2022FY-116.5-122.63-227.420.000.00
2023FY-53.080-12.675-53.0770.000.00
2024FY-9.370-9.249-9.3702.270.00
2025FY-12.480-9.030-12.4806.405.52
2026FY--4.888--1.56
2027FY--4.802--0.00
2028FY--4.032--0.00
2029FY--4.700--16.16
2030FY--4.948--23.98

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-059211.740.007.84
2026Q4S2026-10-038000.190.001.50
2026Q4S2026-08-268020.190.001.50
2026Q4S2026-08-069020.170.001.50
2026Q4S2026-06-217000.210.001.50
2026Q4S2026-05-279000.510.001.57
2026Q4S2026-05-189110.510.001.57
2026Q4S2026-05-077110.650.001.57
2026Q4S2026-03-136110.760.001.57
2026Q4S2026-02-046100.570.002.00
2026Q4S2026-01-276000.560.002.00
2026Q4S2025-11-136210.560.002.00
2026Q4S2025-11-116000.700.001.50
2026Q4S2025-11-106000.700.001.50

Estimate history

EPS, annual-32.272-30.567-32.097-41.098-123.265-227.421-53.077-9.37-12.481-9.069
Period201720182019202020212022202320242025TTM
EPS, quarterly-2.257-2.261-2.492-2.744-1.923-5.321-1.692-1.074-0.982
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0028.94736.98414.068002.2716.3921.29
Period201720182019202020212022202320242025TTM
Sales, quarterly02.2712.551.461.091.292000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.6270.6270.6170.6790.6920.2688.0179.3779.41713.726
Period201720182019202020212022202320242025MRQ
Shares, quarterly9.3189.3779.3899.3919.3989.41714.42314.70613.726
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1.296.392.270.000.0014.0736.9828.950.00
Cost of Goods Sold Incl. D&A1.834.283.563.632.513.841.5816.810.65
Gross Profit-0.542.11-1.29-3.63-2.5110.2335.4012.13-0.65
Selling, General and Administrative Excl. Other74.3589.4590.6280.9056.4994.2662.9532.8118.29
Research and Development47.8061.3060.0753.6239.6959.3236.6618.3311.58
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-74.89-87.34-91.91-84.53-59.00-84.03-27.55-20.68-18.94
Interest Expense0.000.000.000.000.960.76--0.11
Unusual Expense34.5134.510.000.000.000.000.000.000.27
Net Income Before Taxes-105.03-116.62-83.44-81.14-58.02-84.67-26.48-18.75-19.17
Income Taxes1.100.640.140.030.010.010.040.000.00
Consolidated Net Income-106.13-117.26-83.58-81.17-58.03-84.69-26.51-18.75-19.17
Net Income From Continuing Operations-106.13-117.26-83.58-81.17-58.03-84.69-26.51-18.75-19.17
Net Income-106.13-117.26-83.58-81.17-58.03-84.69-26.51-19.80-19.17
EPS (Recurring)-4.59-9.91-9.37-53.08-227.42-123.26-41.10-32.10-30.27
EPS (Basic, Before Extraordinaries)-9.07-12.48-9.37-53.08-227.42-123.26-41.10-32.10-30.57
EPS (Diluted)-9.07-12.48-9.37-53.08-227.42-123.26-41.10-32.10-30.57
EBITDA-73.06-83.06-88.34-80.90-56.49-80.19-25.97-19.86-18.29
Non-Operating Income (Expense)4.375.238.473.390.980.121.071.930.15
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.156.053.521.880.8915.887.292.630.46
Price To Sales Ratio137.0511.77149.54--12.5330.7518.68-
Gross Margin-41.5633.04-56.98--72.7095.7341.92-
Operating Margin-5,796.05-1,366.43-4,047.12---597.32-74.49-71.42-
Net Margin-8,214.47-1,834.48-3,680.36---601.98-71.68-68.40-
Shares Outstanding13.739.429.388.020.270.690.680.620.63
Market Capitalization215.90215.90356.65383.99135.76177.561,197.57540.70552.59

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.001.291.091.462.552.27
Cost of Goods Sold Incl. D&A0.400.400.380.651.201.201.231.25
Gross Profit-0.40-0.40-0.380.64-0.110.261.321.02
Selling, General and Administrative Excl. Other18.0619.7120.0616.5319.1327.4626.3424.06
Research and Development11.7013.1912.5710.3412.6219.8318.5115.71
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-18.46-20.11-20.44-15.88-19.24-27.20-25.02-23.04
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.0034.510.000.000.000.00
Net Income Before Taxes-17.29-18.81-19.53-49.41-18.06-25.77-23.39-21.10
Income Taxes0.260.110.100.640.000.000.000.10
Consolidated Net Income-17.55-18.92-19.62-50.04-18.06-25.77-23.39-21.20
Net Income From Continuing Operations-17.55-18.92-19.62-50.04-18.06-25.77-23.39-21.20
Net Income-17.55-18.92-19.62-50.04-18.06-25.77-23.39-21.20
EPS (Recurring)-0.98-1.07-1.69-2.75-1.92-2.74-2.49-2.26
EPS (Basic, Before Extraordinaries)-0.98-1.07-1.69-5.32-1.92-2.74-2.49-2.26
EPS (Diluted)-0.98-1.07-1.69-5.32-1.92-2.74-2.49-2.26
EBITDA-18.06-19.71-20.06-15.23-18.04-26.00-23.80-21.79
Non-Operating Income (Expense)1.171.300.910.991.181.431.631.94
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.222.142.161.641.821.581.391.07
Price To Sales Ratio137.0597.4934.1711.7861.0218.6733.89157.20
Gross Margin---49.77-10.0917.8151.9644.83
Operating Margin----1,229.33-1,764.86-1,863.15-981.18-1,014.53
Net Margin----3,873.22-1,656.97-1,765.07-917.14-933.47
Shares Outstanding13.7314.7114.429.429.409.399.399.38
Market Capitalization215.90190.09163.2675.43449.73117.29163.46356.65

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments76.16126.09169.7155.85130.71220.34217.3542.1917.94
Short Term Receivables0.971.700.000.000.140.340.810.160.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets5.253.743.021.233.904.383.190.590.02
Total Current Assets82.37131.53172.7357.08134.75225.06221.3542.9417.95
Net Property, Plant & Equipment16.2251.5542.8111.8936.8737.841.761.511.73
Total Investments and Advances12.4440.373.414.5413.421.820.000.000.00
Intangible Assets-----0.00---
Deferred Tax Assets2.20--------
Other Assets2.472.802.710.230.320.000.100.100.10
Total Assets115.71226.24221.6673.74185.36264.72223.2244.5519.79
Short Term Debt Incl. Current Port. of LT Debt2.671.281.992.922.580.400.000.000.00
Accounts Payable1.653.997.282.602.755.511.221.860.99
Other Current Liabilities7.619.6810.213.176.1020.7351.561.911.23
Total Current Liabilities11.9414.9619.488.7011.4326.6352.783.772.23
Long Term Debt40.8143.4831.22164.0743.0245.600.0084.9446.69
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities2.20--------
Other Liabilities9.327.381.050.000.090.003.080.350.51
Total Liabilities64.2765.8351.75172.7754.5372.2355.8689.0649.43
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity51.44160.41169.91-99.03130.82192.49167.36-48.28-29.64
Total Shareholders Equity51.44160.41169.91-99.03130.82192.49167.36-48.28-29.64
Accumulated Minority Interest0.000.000.000.000.000.000.003.770.00
Total Equity51.44160.41169.91-99.03130.82192.49167.36-44.51-29.64
Total Liabilities & Stockholders Equity115.71226.24221.6673.74185.36264.72223.2244.5519.79
Book Value Per Share5.4617.1121.20-368.87188.99283.38271.29-76.99-47.27
Tangible Book Value Per Share5.4617.1121.20-368.87188.99283.38271.29-76.99-47.27
Full-Time Employees5810410148728747--
Price to Book Ratio2.441.970.961.661.366.223.23-9.26-
Return on Assets-68.58-37.32-47.34-44.80-37.63-10.87-14.00-59.59-
Return on Equity-110.70-50.61-67.90-365.06-52.39-14.73-31.49--
Return on Invested Capital-127.11-40.99-40.36-89.22-48.71-11.13-11.20-52.30-118.68
Quick Ratio6.908.798.876.5611.798.454.1911.388.07
Current Ratio6.908.798.876.5611.798.454.1911.388.07

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-106.13-117.26-83.58-81.17-58.03-84.69-26.51-18.75-19.17
Depreciation1.754.283.563.632.513.841.580.810.65
Other Funds (Non Cash)42.1138.846.355.982.5122.119.983.500.67
Funds from Operations-62.27-74.14-73.67-71.57-53.01-58.73-14.95-14.43-17.84
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.44-4.4313.594.28-0.63-17.33-30.2448.650.82
Cash from Operating Activities-63.70-78.56-60.07-67.28-53.65-76.06-45.1934.22-17.02
Capital Expenditures-0.17-0.52-17.90-7.84-5.21-2.91-6.67-1.06-0.44
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.003.77
Purchase or Sale of Investments-6.8044.51-105.4419.0016.27-63.2117.07-17.200.00
Purchase of Investments-87.00-26.19-146.340.00-37.21-92.44-26.34-282.620.00
Sale Or Maturity of Investments80.2070.7040.9019.0053.4829.2343.42265.420.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-6.9643.99-123.3511.1611.06-66.1310.40-18.263.34
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock85.670.6969.36163.410.061.3641.69142.0132.94
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock85.670.6969.36163.410.061.3641.69142.0132.94
Proceedsfrom Stock Options85.280.0067.39162.710.001.3041.69142.0132.94
Issuance or Reduction of Debt, Net0.000.000.000.000.000.0015.000.005.00
Change in Long Term Debt0.000.000.000.000.000.0015.000.005.00
Issuance of Long Term Debt0.000.000.000.000.000.0015.000.005.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.0024.35-0.040.000.000.000.00
Other Financing Activities Uses0.000.000.00-12.25-0.040.000.000.000.00
Cash from Financing Activities85.670.6969.36187.760.021.3656.69142.0137.94
Exchange Rate Effect0.060.06-0.00------
Net Change in Cash15.06-33.82-114.07131.64-42.57-140.8321.90157.9724.25
Free Cash Flow-63.87-79.08-77.98-75.12-58.86-78.97-51.8633.15-17.46
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00-0.00
Price to Free Cash Flow-------16.31-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments104.99115.04114.9776.1693.4897.36
Short Term Receivables0.000.000.000.970.821.09
Inventories0.000.000.000.000.000.00
Other Current Assets3.945.595.195.253.934.18
Total Current Assets108.94120.63120.1682.3798.23102.63
Net Property, Plant & Equipment14.5815.0515.6216.2247.7348.91
Total Investments and Advances22.2425.2945.4912.4412.4225.67
Deferred Tax Assets---2.20--
Other Assets2.372.472.352.473.173.21
Total Assets148.12163.45183.62115.71161.55180.43
Short Term Debt Incl. Current Port. of LT Debt3.072.942.802.673.152.42
Accounts Payable3.303.601.961.652.305.16
Other Current Liabilities8.556.0910.037.619.199.59
Total Current Liabilities14.9212.6314.7911.9414.6417.17
Long Term Debt38.4539.2840.0840.8141.5242.21
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---2.20--
Other Liabilities6.378.319.129.326.365.94
Total Liabilities59.7560.2263.9964.2762.5265.32
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity88.37103.23119.6351.4499.03115.10
Total Shareholders Equity88.37103.23119.6351.4499.03115.10
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity88.37103.23119.6351.4499.03115.10
Total Liabilities & Stockholders Equity148.12163.45183.62115.71161.55180.43
Book Value Per Share6.447.028.295.4610.5412.26
Tangible Book Value Per Share6.447.028.295.4610.5412.26
Full-Time Employees585749588792
Price to Book Ratio2.441.592.070.763.910.84
Return on Assets-68.54-62.03-58.83-68.58-43.65-42.49
Return on Equity-113.26-97.69-87.78-110.70-63.46-58.34
Return on Invested Capital-13.84-13.27-12.29-54.24-12.85-16.38
Quick Ratio7.309.558.136.906.715.98
Current Ratio7.309.558.136.906.715.98

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-17.55-18.92-19.62-50.04-18.06-25.77
Depreciation0.360.360.380.651.181.23
Other Funds (Non Cash)3.052.952.9833.141.962.17
Funds from Operations-14.14-15.61-16.27-16.25-14.93-22.38
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.20-1.390.20-1.45-2.253.15
Cash from Operating Activities-12.94-16.99-16.07-17.70-17.18-19.23
Capital Expenditures-0.03-0.04-0.02-0.08-0.17-0.14
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments28.29-17.86-32.2215.007.77-11.16
Purchase of Investments-11.91-29.86-45.220.00-15.03-11.16
Sale Or Maturity of Investments40.2012.0013.0015.0022.800.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities28.26-17.90-32.2414.927.60-11.30
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.00-2.9288.210.380.130.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.00-2.9288.210.380.130.01
Proceedsfrom Stock Options0.00-2.9288.190.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.00-2.9288.210.380.130.01
Exchange Rate Effect-0.010.02-0.030.07-0.00-
Net Change in Cash15.31-37.7939.87-2.33-9.46-30.53
Free Cash Flow-12.96-17.03-16.09-17.79-17.35-19.37

Revenue breakdown

Pharmaceutical Preparations2024: 2.27M 2025: 6.39M
United States2024: 2.27M 2025: 6.39M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3018.28%1.7M9.6M162.22K
2026-10-1516.87%1.7M10.3M153.25K
2026-09-3016.31%1.7M10.3M160.70K
2026-09-1515.11%1.6M10.3M177.08K
2026-08-3114.52%1.5M10.2M178.71K
2026-08-1414.84%1.5M10.2M194.78K
2026-07-3113.85%1.4M10.4M194.45K
2026-07-1515.84%1.5M9.2M179.41K
2026-06-3016.92%1.7M10.1M178.94K
2026-06-1513.33%1.3M9.9M152.40K
2026-05-2913.21%1.3M9.6M178.15K
2026-05-1512.37%1.2M9.7M177.04K
2026-04-3010.38%1.1M10.8M186.66K
2026-04-1513.86%1.1M7.8M247.17K
2026-03-3113.05%1.1M8.1M241.15K
2026-03-1312.51%1.0M8.1M237.86K
2026-02-2719.60%1.0M5.3M266.62K
2026-02-1320.05%1.1M5.3M360.09K
2026-01-3022.22%1.1M5.1M548.98K
2026-01-1521.19%1.1M5.2M504.68K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5010.5014.500.000.0000.000.000.970-0.0990.002
call5.008.0012.000.0013.1900.000.000.997-0.0390.000
call7.506.308.606.803.7342001.000.923-0.2680.003
call10.003.107.000.456.16460.000.000.847-0.3050.005
call12.501.754.901.752.0075.005.000.757-0.2920.007
call15.000.004.900.003.4160.000.000.596-0.1950.009
call17.500.004.900.306.69148.000.000.631-0.3210.008
call20.000.004.900.007.3250.000.000.612-0.3570.009
call22.500.001.700.104.2165.000.000.363-0.2010.008
call25.000.004.900.004.6450.000.000.345-0.2170.008
put2.500.000.700.005.9270.000.00-0.008-0.0170.001
put5.000.004.900.000.0000.000.00-0.067-0.1830.003
put7.500.004.900.3014.8644.000.00-0.071-0.2620.003
put10.000.004.900.0010.3630.000.00-0.140-0.3100.005
put12.500.004.900.007.3560.000.00-0.243-0.2910.007
put15.000.004.902.155.1885.000.00-0.404-0.1930.009
put17.501.204.900.003.2010.000.00-0.482-0.2160.009
put20.003.007.000.003.3830.000.00-0.388-0.3540.009
put22.505.509.400.003.7700.000.00-0.637-0.1990.008
put25.008.0012.000.004.3180.000.00-0.655-0.2150.008

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-03SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-264Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-228-KCurrent report2026-10-22SEC
2026-10-058-KCurrent report2026-10-05SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-26144Filing for proposed sale of securities under Rule 144.SEC
2026-08-26144Filing for proposed sale of securities under Rule 144.SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-198-KCurrent report2026-08-19SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-05SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10884.75K300
2026-0900785.61K5
2026-0878.81K2495.57K4
2026-07001.54M2
2026-06002.64M7
2026-0500236.57K2
2026-040000
2026-0320.71M1000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Lynx1 Capital Management LP10.67%
Nantahala Capital Management, LLC9.15%
NEA Management Company, LLC9.00%
Venrock Adviser, LLC7.00%
BALYASNY ASSET MANAGEMENT L.P.6.60%
BlackRock, Inc.5.67%
Atlas Venture Life Science Advisors, LLC5.25%
Affinity Asset Advisors, LLC4.90%
ADAGE CAPITAL PARTNERS GP, L.L.C.3.75%
ADAR1 Capital Management, LLC3.74%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND3.11%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.16%
iShares Russell 2000 ETF1.82%
Fidelity Small Cap Index Fund0.85%
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND0.74%
iShares Russell 2000 Value ETF0.55%
F/m Emerald Life Sciences Innovation ETF0.44%
VANGUARD RUSSELL 2000 INDEX FUND0.43%
Fidelity Extended Market Index Fund0.42%
iShares Russell 2000 Growth ETF0.39%

OakChart. KRRO. Cached 15 minutes.